# Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

> **NCT03176238** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 235 (actual)

## Conditions studied

- Post Menopausal Breast Cancer

## Interventions

- **DRUG:** everolimus
- **DRUG:** exemestane

## Key facts

- **NCT ID:** NCT03176238
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-29
- **Primary completion:** 2019-01-29
- **Final completion:** 2019-01-29
- **Target enrollment:** 235 (ACTUAL)
- **Last updated:** 2020-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03176238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03176238, "Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03176238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*